EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY 4.0

Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS)

Théo Erard, Gaelle Quéreux, Mona Amini-Adle, Henri Montaudié, Julie Charles, Marc Puyraveau, Géraldine Jeudy, Philippe Bernard, Florent Grange, Delphine Legoupil, Ouidad Zehou, Philippe Celerier und 4 weitere

European Journal of Cancer · 2026-08 · 244 · 116878

DOI: 10.1016/j.ejca.2026.116878 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2026-08. Verfasst von Théo Erard und 15 weiteren Autor:innen. Beteiligte Einrichtung: Dermatologie, Centre hospitalier universitaire de Besançon, INSERM UMR 1098 RIGHT, Université Marie et Louis Pasteur, Besançon, France k Dermatologie…. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Immune Checkpoint Inhibitors, Protein Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsImmune Checkpoint InhibitorsProtein Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedChemotherapy, AdjuvantRetrospective StudiesMaleAgedNeoplasm StagingAdultProto-Oncogene Proteins B-rafFrance

Stichwörter der Autor:innen

Adjuvant treatmentAnti-PD-1BRAF V600BRAFi/MEKiImmunotherapyMelanomaOverall survivalRecurrence-free survival

Substanzen

Immune Checkpoint InhibitorsProtein Kinase InhibitorsProto-Oncogene Proteins B-raf

Autor:innen und Institutionen

  • Dermatologie, Centre hospitalier universitaire de Besançon, INSERM UMR 1098 RIGHT, Université Marie et Louis Pasteur, Besançon, France k Dermatologie, Hôpital Henri-Mondor AP-HP, Créteil, France.
  • Service de dermatologie, CHU de Nantes, Université de Nantes, CIC 1413T, Inserm UMR 1302/EMR6001 INCI, Nantes, France.
  • Dermatologie, Centre Léon Bérard, Lyon, France.
  • Dermatologie, Hôpital l'Archet, Nice, France.
  • Dermatologie, CHU Grenoble Alpes, La Tronche, France.
  • uMETh, CIC, CHU, Besançon 1431, France.

Zitieren

APA

Erard, T., Quéreux, G., Amini-Adle, M., Montaudié, H., Charles, J., Puyraveau, M., Jeudy, G., Bernard, P., Grange, F., Legoupil, D., Zehou, O., Celerier, P., Lesage, C., Khammari, A., Aubin, F., & Nardin, C. (2026). Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS). European Journal of Cancer, 244, 116878. https://doi.org/10.1016/j.ejca.2026.116878

Vancouver

Erard T, Quéreux G, Amini-Adle M, Montaudié H, Charles J, Puyraveau M, et al. Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS). European Journal of Cancer. 2026;244:116878. doi:10.1016/j.ejca.2026.116878

BibTeX
@article{Erard2026,
  author = {Erard, Théo and Quéreux, Gaelle and Amini-Adle, Mona and Montaudié, Henri and Charles, Julie and Puyraveau, Marc and Jeudy, Géraldine and Bernard, Philippe and Grange, Florent and Legoupil, Delphine and Zehou, Ouidad and Celerier, Philippe and Lesage, Candice and Khammari, Amir and Aubin, François and Nardin, Charlée},
  title = {Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS)},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {244},
  pages = {116878},
  doi = {10.1016/j.ejca.2026.116878}
}
Kostenlos starten →